elesclomol

08/01/2008 - "Elesclomol (formerly STA-4783) is a novel small molecule undergoing clinical evaluation in a pivotal phase III melanoma trial (SYMMETRY). "
11/01/2016 - "Although knockdown of MTH1 did not impinge on the viability of melanoma cells, it rendered melanoma cells sensitive to apoptosis induced by the oxidative stress inducer elesclomol. "
10/01/2012 - "Cotreatment of melanomas with DCA and elesclomol in vivo achieved a more durable response than single agent alone. "
01/01/2012 - "We also provide evidence that melanoma cells with high levels of glycolysis are more resistant to Elesclomol. "
01/01/2019 - "Elesclomol is an investigational agent for melanoma and other malignancies. "

11/01/2023 - "We summarize our current knowledge of the tumor suppressive mechanisms of elesclomol, with emphasis on cuproptosis. "
10/20/2023 - "Elesclomol (ELC) is a mitochondrion-targeting agent discovered for the treatment of solid tumors. "
10/20/2023 - "Combining elesclomol with AGK2, a SIRT2-specific inhibitor, induce cuproptosis in gastric tumors in vitro and in vivo. "
03/01/2023 - "In vivo experiments, 4-OI with elesclomol-Cu showed better anti-tumor effects. "
03/01/2023 - "The anti-tumor effect of elesclomol with 4-OI was verified in vivo assay. "

01/01/2020 - "Through this mechanism, elesclomol prevented detrimental neurodegenerative changes and improved the survival of the mottled-brindled mouse-a murine model of severe Menkes disease. "
01/01/2022 - "Recent groundbreaking studies have demonstrated that a copper delivery small molecule compound, elesclomol (ES), is able to substantially ameliorate pathology and lethality in a mouse model of Menkes disease when injected as an ES-Cu2+ complex. "
01/01/2023 - "Recent studies have uncovered the therapeutic potential of elesclomol, a copper ionophore, for the treatment of copper deficiency disorders such as Menkes disease. "

01/01/2019 - "Here, we demonstrate that elesclomol is relatively potent against Mtb H37Rv with minimum inhibitory concentration of 10 μM (4 mg/L) and against multidrug resistant clinical isolates of Mtb, displays additive interactions with known tuberculosis drugs such as isoniazid and ethambutol, and a synergistic interaction with rifampicin. "

01/01/2017 - "Re-expression of PDK3 in NAC1 absent cells rescued cells from hypoxia-induced metabolic stress and restored the activity of glycolysis in a xenograft mouse model, and demonstrated that silencing of NAC1 expression can enhance the antitumor efficacy of elesclomol, a pro-oxidative agent. "
01/01/2017 - "Silencing of NAC1 Expression Induces Cancer Cells Oxidative Stress in Hypoxia and Potentiates the Therapeutic Activity of Elesclomol."